ArticleOncogene2006
Mitochondrially targeted wild-type p53 suppresses growth of mutant p53 lymphomas in vivo.
Article in Oncogene, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 31 citations in OpenAlex.
- Molecular Subtypes and the Role of TP53 in Diffuse Large B-Cell Lymphoma and Richter Syndrome.Cancers · 2024Review
- A full-proteome, interaction-specific characterization of mutational hotspots across human cancers.Genome research · 2022Article
- Ouabain-induced apoptosis in cochlear hair cells and spiral ganglion neurons in vitro.BioMed research international · 2013Article
- Article
- The mitochondrial p53 pathway.Biochimica et biophysica acta · 2009Review
- The p53 family and programmed cell death.Oncogene · 2008Review
- Mitochondrially targeted wild-type p53 induces apoptosis in a solid human tumor xenograft model.Cell cycle (Georgetown, Tex.) · 2008Article
- Oligomerization of BAK by p53 utilizes conserved residues of the p53 DNA binding domain.The Journal of biological chemistry · 2008Article
- p53's mitochondrial translocation and MOMP action is independent of Puma and Bax and severely disrupts mitochondrial membrane integrity.Cell research · 2008Article
- Resistance of mitochondrial p53 to dominant inhibition.Molecular cancer · 2008Article
- Blocking mitochondrial permeability transition prevents p53 mitochondrial translocation during skin tumor promotion.FEBS letters · 2008Article
- Monoubiquitylation promotes mitochondrial p53 translocation.The EMBO journal · 2007Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The complex apoptotic functions of the p53 tumor suppressor are central to its antineoplastic activity in vivo. Besides its well-known action as a transcriptional activator of apoptotic genes, p53 exerts a direct proapoptotic role at the mitochondria via protein-protein interactions with Bcl2 family members, thus executing the shortest known circuitry of p53 death signaling. We recently reported that exclusive delivery of p53 to mitochondria exerts a significant in vivo tumor suppressor activity in p53-null lymphomas. However, it was unknown whether mitochondrially targeted p53 has suppressor activities in tumors harboring missense mutants, which constitute the vast majority of p53 alterations in human tumors. Here, we show that targeting p53 to mitochondria does confer a significant growth disadvantage in B-lymphomas expressing various point mutants of p53, resulting in efficient apoptosis induction in vitro and in vivo in mice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.